Fosun Wanbang | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

164 results for “Fosun Wanbang”

Trials

View all 36 →

Online Training for the Reconstitution of Fosun/BioNTech

385 participants · First posted Apr 8, 2022

Study on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction

200 participants · First posted Jan 6, 2021

Bidirectional Cohort Study of Nanfang Spondyloarthritis

3,000 participants · First posted May 25, 2025

Drugs

View all 61 →

Liraglutide biosimilar(Wanbang Biopharmaceuticals)

Semaglutide biosimilar (Jiangsu Wanbang)

Tetanus vaccines(Shanghai Fosun Pharmaceutical)

Organizations

View all 14 →

Wanbang Biopharmaceuticals

China

Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

China

FOSUN INDUSTRIAL CO., LIMITED

Hong Kong, China

News

View all 53 →

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang in Greater China Deal Worth Up to RMB 215 Million Upfront

Sisram Medical's DAXXIFY Clears Final Regulatory Hurdle for China Market Launch

Fosun Pharma and MingMed Achieve Key Regulatory Milestones for Novel Therapies

Page 1 of 17